Table 1 General characteristics of patients in IgAN, MN and MCD groups
Parameters | IgAN | MN | MCD | Total | P value | ||
|---|---|---|---|---|---|---|---|
Gender, n (female, %) | 88(34.1) | 100(41.0) | 48(37.5) | 236(100) | 0.621 | ||
age, year(95% CI) | 38.1(35.8–40.6) | 48.3(45.3–51.2) | 36.9(32.7–41.1) | – | 6.34E-6 | ||
IF intensity grade | IgG | Neg | 71(80.7%) | 7(7.0%) | 48(100.0%) | 126(53.4%) | 4.60E-39 |
+ | 17(19.3%) | 16(16.0%) | 0(0.0%) | 33(14.0%) | |||
++ | 0(0.0%) | 77(77.0%) | 0(0.0%) | 77(32.6%) | |||
IgM | Neg | 84(95.5%) | 99(99.0%) | 47(97.9%) | 230(97.5%) | 0.297 | |
+ | 4(4.5%) | 1(1.0%) | 1(2.1%) | 6(2.5%) | |||
IgA | Neg | 0(0.0%) | 91(91.0%) | 48(100%) | 139(58.9%) | 9.82E-43 | |
+ | 32(36.4%) | 5(5.0%) | 0(0.0%) | 37(15.7%) | |||
++ | 56(63.6%) | 4(4.0%) | 0(0.0%) | 60(25.4%) | |||
C3 | Neg | 27(30.7%) | 39(39.0%) | 48(100.0%) | 114(48.3%) | 7.45E-15 | |
+ | 50(56.8%) | 58(58.0%) | 0(0.0%) | 108(45.8%) | |||
++ | 11(12.5%) | 3(3.0%) | 0(0.0%) | 14(5.9) | |||
C4 | Neg | 88(100.0%) | 100(100.0%) | 48(100.0%) | 236(100.0%) | – | |
Serum values | Urea, mmol/L | 6.27(5.63–6.92) | 5.47(4.95–5.99) | 6.25(5.13–7.38) | – | 0.045 | |
Crea, μmol/L | 111.6(100.1–123.2) | 76.1(71.1–81.0) | 81.7(75.6–87.7) | 3.45E-5 | |||
eGFR, ml/min per 1.73m2 | 83.2(76.2–90.3) | 101.2(96.4–106.0) | 103.4(96.0–110.8) | 0.005 | |||
sIgG, mg/dL | 1015.4(952.6–1078.1) | 619.0(565.3–672.6) | 518.3(422.0–614.5) | 1.68E-14 | |||
sIgM, mg/dL | 106.8(95.3–118.4) | 129.1(110.4–147.9) | 139.0(121.4–156.6) | 0.014 | |||
sIgA, mg/dL | 308.0(285.9–330.1) | 221.1(203.5–238.8) | 211.7(185.4–237.9) | 9.14E-9 | |||
sC3, mg/dL | 109.2(104.8–113.5) | 116.0(111.0–120.9) | 117.0(110.0–124.0) | 0.124 | |||
sC4, mg/dL | 25.8(24.3–27.3) | 29.9(27.8–32.0) | 28.1(25.0–31.1) | 0.026 | |||